6th January 2020 | Mumbai | Investment Banking
Princeton, New Jersey based Slayback Pharma LLC (“Slayback”) announced that it has entered into an agreement with The Everstone Group (“Everstone”) to invest up to USD 50 million in primary funding. Slayback, founded by Ajay Singh and backed by KKR, has created has a strong portfolio of complex generics and specialty pharmaceuticals products. In 2019, Slayback received approvals for three products. The funds will be used for expansion of the injectable and alternate dosage forms led product portfolio.
Avendus Capital is the exclusive financial advisor to Slayback on this transaction.
Post the transaction, Everstone will join KKR as investor on the board of Slayback.
Ajay Singh, Founder and CEO, Slayback Pharma LLC, said, “We are delighted to partner with Everstone in our quest for smart solutions to complex pharmaceutical challenges. Their experience in investing in and building pharmaceutical businesses with a focus on regulated markets will help turbo-charge our growth pipeline of complex and specialty products. We are especially thrilled to welcome Arjun and Puncham to our board.”
Chintan Kothari, Head of Healthcare Investment Banking at Avendus Capital, said, “We are proud to be associated with Slayback Pharma LLC, which has created a truly differentiated portfolio targeting the US markets. Slayback with its nimble R&D program powered by in house IP, and an asset light manufacturing model, has demonstrated commendable success in a short period.”
About Avendus Capital Pvt Ltd
The Avendus Group (Avendus) is a leading provider of financial services with an emphasis on customized solutions in the areas of Investment Banking, Wealth Management, Structured Credit Solutions and Alternative Assets Management. Avendus relies on its extensive experience, in-depth domain understanding and knowledge of the regulatory environment, to offer customized solutions that enable clients to meet their strategic aspirations. Avendus Capital has consistently been ranked among the top investment banks. It has a strong track record of cross-border transactions and has helped multiple clients benefit from opportunities across geographies. Avendus’ wide range of clients is testimony to its ability to serve its corporate clients throughout their life cycle – from growth stage funding to complex, large sized transactions later in the cycle.
Avendus Capital Inc. and Avendus Capital (UK) Pvt. Ltd. located in New York and London respectively are wholly owned subsidiaries offering M&A and Private Equity syndication services to clients in the respective regions.
For more information, please visit www.avendus.com